Key Takeaways
- • Nervonik closed an oversubscribed Series B financing round of $52.5 million led by Amzak Health, bringing total funding to $65.5 million including a $13 million Series A from March 2025.
- • The Los Angeles-based company develops peripheral nerve stimulation (PNS) technology for chronic pain management, integrating real-time physiological feedback with implantable pulse generators and wearable devices for personalized patient therapy.
- • Early clinical validation includes successful first-in-human study data from 2024 demonstrating the recording of evoked compound action potentials (ECAPs) and other biomarkers, positioning the company in the emerging bioelectronic medicine sector.
- • Additional Series B investors include Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital, indicating broad institutional backing for the neuromodulation platform.
- • Proceeds will fund continued development and commercialization of PNS technology, with emphasis on advancing proprietary sensing capabilities that differentiate Nervonik's platform through precision and personalization.
Summary
Nervonik has secured $52.5 million in Series B funding, closing an oversubscribed round that positions the Los Angeles-based neuromodulation company for accelerated clinical and commercial development. The financing round was led by Amzak Health, with participation from a syndicate of institutional investors including Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital. Combined with the company's $13 million Series A announced in March 2025, Nervonik has now raised $65.5 million to advance its peripheral nerve stimulation platform.
The company's technology applies precisely controlled electrical currents to peripheral nerves to modulate pain signals and deliver chronic pain relief. The system comprises miniaturized implantable pulse generators connected to leads that integrate with a small, programmable wearable device. Patients can receive customized stimulation parameters through a dedicated application, enabling individualized treatment optimization. The platform's differentiation lies in its real-time physiological feedback capability, which enhances both personalization and therapeutic efficacy compared to conventional neuromodulation approaches.
Clinical validation has been demonstrated through a first-in-human study completed in 2024, which successfully recorded evoked compound action potentials (ECAPs) and other biomarkers using implantable leads. This early data supports Nervonik's positioning at the forefront of next-generation bioelectronic medicine. CEO and founder Aydin Babakhani characterized the platform as "fundamentally differentiated," emphasizing the integration of stimulation with advanced sensing to deliver more precise and personalized therapy.
Proceeds from the Series B will support continued development and commercialization of the PNS technology, with specific focus on advancing the company's proprietary sensing capabilities. The robust investor participation and oversubscribed nature of the round underscore institutional confidence in both the technology's clinical merit and the market opportunity in chronic pain management and bioelectronic medicine.
The company's technology applies precisely controlled electrical currents to peripheral nerves to modulate pain signals and deliver chronic pain relief. The system comprises miniaturized implantable pulse generators connected to leads that integrate with a small, programmable wearable device. Patients can receive customized stimulation parameters through a dedicated application, enabling individualized treatment optimization. The platform's differentiation lies in its real-time physiological feedback capability, which enhances both personalization and therapeutic efficacy compared to conventional neuromodulation approaches.
Clinical validation has been demonstrated through a first-in-human study completed in 2024, which successfully recorded evoked compound action potentials (ECAPs) and other biomarkers using implantable leads. This early data supports Nervonik's positioning at the forefront of next-generation bioelectronic medicine. CEO and founder Aydin Babakhani characterized the platform as "fundamentally differentiated," emphasizing the integration of stimulation with advanced sensing to deliver more precise and personalized therapy.
Proceeds from the Series B will support continued development and commercialization of the PNS technology, with specific focus on advancing the company's proprietary sensing capabilities. The robust investor participation and oversubscribed nature of the round underscore institutional confidence in both the technology's clinical merit and the market opportunity in chronic pain management and bioelectronic medicine.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.